Amir Nasrollahizadeh

Dr. Amir Nasrollahizadeh

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
KGKoushik Rao Gadhachanda
Koushik Rao Gadhachanda
MMMohammed Dheyaa Marsool Marsool
Mohammed Dheyaa Marsool Marsool
ABAli Bozorgi
Ali Bozorgi
DADaniyal Ameen
Daniyal Ameen
SNSandeep Samethadka Nayak
Sandeep Samethadka Nayak
ANIL KUMAR JONNALAGADDAANIL KUMAR JONNALAGADDA
ANIL KUMAR JONNALAGADDA
Background: The integration of artificial intelligence (AI) into cardiovascular procedures has significantly advanced diagnostic accuracy, outcome prediction, and robotic-assisted surgeries. However, a comprehensive bibliometric analysis of AI’s impact in this field is lacking. This study examines research trends, key contributors, and emerging themes in AI-driven cardiovascular interventions. Methods: We retrieved relevant publications from the Web of Science Core Collection and analyzed them using VOSviewer, CiteSpace, and Biblioshiny to map research trends and collaborations. Results: AI-related cardiovascular research has grown substantially from 1993 to 2024, with a sharp increase from 2020 to 2023, peaking at 93 publications in 2023. The USA (127 papers), China (79), and England (31) were the top contributors, with Harvard University leading institutional output (17 papers). Frontiers in Cardiovascular Medicine was the most prolific journal. Core research themes included “machine learning,” “mortality,” and “cardiac surgery,” with emerging trends in “association,” “implantation,” and “aortic stenosis,” underscoring AI’s expanding role in predictive modeling and surgical outcomes. Conclusion: AI demonstrates transformative potential in cardiovascular procedures, particularly in diagnostic imaging, predictive modeling, and patient management. This bibliometric analysis highlights the growing interest in AI applications and provides a framework for integrating AI into clinical workflows to enhance diagnostic accuracy, treatment strategies, and patient outcomes.

Verified
Journal Article
Open access
PDF file
KHKaveh Hosseini
Kaveh Hosseini
HSHamidreza Soleimani
Hamidreza Soleimani
ANAmir Nasrollahizadeh
Amir Nasrollahizadeh
YJYaser Jenab
Yaser Jenab
AKAngelos Karlas
Angelos Karlas
PKPolydoros Kampaktsis
Polydoros Kampaktsis
Background: Transcatheter edge-to-edge repair (TEER) of the mitral valve (MV) can be performed using the PASCAL or MitraClip devices. Few studies offer a head-to-head outcome comparison of these two devices. Material and Methods: PubMed, EMBASE, Cochrane Library, Clinicaltrials.gov and WHO’s International Clinical Trials Registry Platform, from 1 January 2000 until 1 March 2023, were searched. Study protocol details were registered in the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD42023405400). Randomized Controlled Trials and observational studies reporting head-to-head clinical comparison of PASCAL and MitraClip devices were eligible for selection. Patients with severe functional or degenerative mitral regurgitation (MR) who had undergone TEER of the MV with either PASCAL or MitraClip devices were included in the meta-analysis. Data from six studies (five observational and one randomized clinical trial) were extracted and analyzed. The main outcomes were a reduction in MR to 2+ or less, improvement of New York Heart Association (NYHA) and 30-day all-cause mortality. Peri-procedural mortality, success rate and adverse events were also compared. Results: Data from 785 and 796 patients that underwent TEER using PASCAL and MitraClip, respectively, were analyzed. Thirty-day all-cause mortality (Risk ratio [RR] = 1.51, 95% CI 0.79–2.89), MR reduction to maximum 2+ (RR = 1.00, 95% CI 0.98–1.02) and NYHA improvement (RR = 0.98, 95% CI 0.84–1.15) were similar in both device groups. Both devices had high and similar success rates (96.9% and 96.7% for the PASCAL and MitraClip group, respectively, p value = 0.91). MR reduction to 1+ or less at discharge was similar in both device groups (RR = 1.06, 95% CI 0.95–1.19). Composite peri-procedural and in-hospital mortality was 0.64% and 1.66% in the PASCAL and MitraClip groups, respectively (p value = 0.094). Rates of peri-procedural cerebrovascular accidents were 0.26% in PASCAL and 1.01% in MitraClip (p value = 0.108). Conclusions: Both PASCAL and MitraClip devices have high success and low complication rates for TEER of the MV. PASCAL was not inferior to MitraClip in reducing the MR level at discharge.

3 April 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
RARamin Abrishami
Ramin Abrishami
SASeyed Hadi Aghili
Seyed Hadi Aghili
CACyrus Afshar
Cyrus Afshar
MRMehri Farhang Ranjbar
Mehri Farhang Ranjbar
ANAmir Nasrollahizadeh
Amir Nasrollahizadeh
MPMohammad Poursalehian
Mohammad Poursalehian
Background: Although conversion arthroplasty of fused hips can relieve pain and provide patient satisfaction, long-term outcomes of total hip arthroplasty (THA) after hip fusion remain a subject of debate. This meta-analysis aimed to assess the effectiveness of THA for fused hips over a long period with concerns over potential complications. Methods: A systematic search of five databases from 2000 until 2023 identified English studies evaluating THA for fused hips with at least 100 months of follow-up. Meta-analyses were conducted using random-effect models via the comprehensive meta-analysis software. Sensitivity analysis, in-depth meta-regression, Egger's test, and the trim-and-fill method were performed appropriately Results: The meta-analysis assessed 790 patients and 889 hips with a mean follow-up of 11 years. At the final follow-up, the mean Harris Hip Score (HHS) and leg length discrepancy (LLD) improved by 34.755 and 2.3 cm from the baseline, respectively. Regarding survival of hip fusion conversion to THA, most studies (88.8%) reported a 5-year implant survival rate of at least 90%, and the 15-year and 20-year implant survival rates, ranged between 80–90% and 70–90%, respectively. Subjective dissatisfaction with the conversion of hip fusion to THA was only 5.3%. Composite rates of revision, instability, and aseptic loosening were 13.6%, 3.8%, and 8.8%, respectively. Conclusions: Conversion of fused hips to THA results in favourable long-term outcomes regarding HHS, LLD, survival rates, and subjective satisfaction, leading to improved quality of life in properly selected patients. However, the presence of complications should be considered when evaluating the overall success of the procedure.

24 March 2025 in Clinical Cardiology
Verified
Journal Article
Open access
PSParsa Saberian
Parsa Saberian
RCRafael Contreras
Rafael Contreras
AGAnoop Gurram
Anoop Gurram
ANAmir Nasrollahizadeh
Amir Nasrollahizadeh
NKNarsimha Rao Keetha
Narsimha Rao Keetha
DADaniyal Ameen
Daniyal Ameen
Background: Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic valve replacement (SAVR) for high‐risk patients with severe aortic stenosis (AS). However, the clinical outcomes and prognostic implications of TAVR in patients with active cancer remain uncertain. This meta‐analysis evaluates procedural success, complications, and survival outcomes of TAVR in patients with and without active cancer.Methods: A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science databases. Statistical analysis was performed using a random‐effects model. Statistical analyses were conducted using STATA version 18.0.Results: The results of the meta‐analysis showed no significant difference in in‐hospital mortality between cancer and non‐cancer patients (OR = 1.17; 95% CI: 0.83, 1.65; p = 0.27). Similarly, 30‐day mortality did not differ between the two groups (OR = 0.93; 95% CI: 0.72, 1.19; p = 0.49). However, 1‐year mortality was significantly higher in cancer patients (OR = 1.93; 95% CI: 1.45, 2.56; p < 0.01). Two‐year mortality was also higher in cancer patients (OR = 2.65; 95% CI: 1.79, 3.93; p < 0.01). No significant differences were observed in major bleeding, acute kidney injury, stroke, or permanent pacemaker implantation between the groups.Conclusion: While TAVR offers comparable in‐hospital and short‐term survival outcomes for cancer and non‐cancer patients, long‐term mortality is significantly higher in those with active cancer. These findings suggest that TAVR is a viable option for cancer patients with severe AS but requires careful long‐term prognostic considerations. Further studies are needed to optimize management strategies for this complex population.

30 April 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
HSHamidreza Soleimani
Hamidreza Soleimani
EKElaheh Karimi
Elaheh Karimi
MMMehrdad Mahalleh
Mehrdad Mahalleh
FEFatemeh Jodeiri Entezari
Fatemeh Jodeiri Entezari
ANAli Nasrollahizadeh
Ali Nasrollahizadeh
KHKaveh Hosseini
Kaveh Hosseini
Dual antiplatelet therapy (DAPT), combining aspirin and a P2Y12 receptor inhibitor, is a standard post-percutaneous coronary intervention (PCI) treatment to reduce thrombosis and ischemic events. However, the optimal DAPT duration remains unclear, with concerns about bleeding risks associated with long-term potent P2Y12 inhibitors. This systematic review and meta-analysis investigates the safety and efficacy of shortened DAPT regimens. A comprehensive search of PubMed, Scopus, and EMBASE identified randomized controlled trials (RCTs) comparing conventional DAPT (≥ 12 months) and abbreviated DAPT (≤ 3 months) post-PCI. Primary outcomes were 1-year all-cause mortality and bleeding, assessed using the Bleeding Academic Research Consortium (BARC) classification. Secondary outcomes included cardiovascular mortality, non-fatal myocardial infarction (MI), stroke, and major adverse cardiovascular events (MACE). Risk of bias was assessed with the Cochrane tool, and meta-analyses used random-effects models. Forty studies involving 54,233 participants were included. Abbreviated DAPT significantly reduced all-cause mortality (RR: 0.90, 95%CI: 0.82–0.98) and bleeding (BARC 3 or 5: RR: 0.77, 95%CI: 0.60–0.97). No significant differences were observed in cardiovascular mortality, stroke, non-fatal MI, revascularization, or in-stent thrombosis. Subgroup analyses showed lower mortality with 1-month DAPT and reduced bleeding in patients with high bleeding risk, acute coronary syndrome (ACS), and complex PCI. Abbreviated DAPT post-PCI is associated with lower all-cause mortality and bleeding without compromising ischemic protection, supporting its use in specific patient populations. Individualized DAPT durations should be considered to balance bleeding and ischemic risks.

11 October 2023 in Clinical Cardiology
Verified
Journal Article
Open access
ANAmir Nasrollahizadeh
Amir Nasrollahizadeh
HSHamidreza Soleimani
Hamidreza Soleimani
SHSeyedeh Melika Hashemi
Seyedeh Melika Hashemi
KHKaveh Hosseini
Kaveh Hosseini
Pulmonary arterial hypertension (PAH) is a widespread condition that affects around 1% of the global population, with a higher prevalence among older individuals. The approach to managing PAH has undergone significant changes, requiring extensive treatment strategies. Sotatercept, an FDA‐approved medication, has recently attracted attention for its potential role in PAH therapy. However, information on its safety and effectiveness is scarce. In this study, we performed a meta‐analysis of existing randomized clinical trials to assess the impact of Sotatercept on PAH patients. Our findings revealed that those treated with Sotatercept showed greater improvement in pulmonary vascular resistance and World Health Organization functional class compared with placebo recipients. The occurrence of adverse events was similar between both groups. Importantly, the Sotatercept group displayed a considerably higher number of cases with an increase in hemoglobin levels. Considering that about 33% of PAH patients experience anemia and both anemia and polycythemia can adversely affect disease prognosis, additional research is necessary to establish the potential advantages and disadvantages of Sotatercept as a treatment choice, specifically regarding its erythropoietic properties.